Pro Nephro AKI (NGAL) is now FDA-Cleared     READ MORE

Governance

COMPANY ARTICLES

Please find the newest company articles here: BioPorto A/S – Articles of Association

Danish

Corporate Governance

BioPorto is subject to the recommendations prepared by the Committee on Corporate Governance, which are available at www.corporategovernance.dk.

The Board of Directors regularly assesses how the recommendations may contribute to strengthening the management of BioPorto and ensure maximum value creation for the company’s shareholders. Once a year, the Board of Directors reviews the recommendations, evaluating BioPorto’s degree of compliance. The Board of Directors believes that BioPorto complies with all of the recommendations of the Committee.

The 2023 Statutory report on Corporate Governance can be downloaded here.

Board Members

Individual board member biographies can be found on About BioPorto.

Summary

Board MemberFirst ElectedTerm ExpiresIndependentNationalityYear of BirthGender
John McDonough20212025YesUSA1959M
Don Hardison20212025YesUSA1950M
Michael Singer20192025YesUSA1973M
Ninfa M. Saunders20232025YesUSA1959F
Henrik Juuel20242025YesDenmark1965M
Mats Thorén20242025YesSweden1971M
2022 MeetingsBoard of DirectorsRemuneration CommitteeNomination CommitteeAudit Committee*Strategy CommitteeBusiness, Research and Development Committee
ChairChristopher LindopDon HardisonChristopher LindopJohn McDonoughChristopher LindopMichael Singer
Christopher Lindop20/201/31/16/615/51/1
John McDonough19/202/31/16/65/51/1
Don Hardison220/202/30/15/51/1
Jan Leth Christensen20212023YesDenmark1963M
Michael Singer19/206/65/51/1
Jan Leth Christensen19/205/51/1
Peter Mørch Eriksen20/205/51/1

*Includes one meeting with the external Auditors.

Participation in Committee Meetings is compensated with an additional remuneration of DKK 25,000 per Committee per year, with an overall maximum of DKK 50,000 per Board Member. The Chairman and Vice-Chairman are not entitled to receive additional remuneration for Committee membership.